{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:54:54Z","timestamp":1794246894763,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ijid.2025.108321","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:13:35Z","timestamp":1766121215000},"page":"108321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate: Real-world assessment of effectiveness and weight Gain in na\u00efve people living with HIV of Asian OrigiN (DRAGON)"],"prefix":"10.1016","volume":"164","author":[{"given":"Chia-Jui","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hsin","family":"Hsih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Wang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Chia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Song","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hsing","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung-Che","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1886-0370","authenticated-orcid":false,"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2025.108321_bib0001","unstructured":"UNAIDS. Latest global and regional statistics on the status of the AIDS epidemic. 2025. https:\/\/www.unaids.org\/en\/resources\/documents\/2025\/UNAIDS_FactSheet [accessed 14 November 2024]."},{"key":"10.1016\/j.ijid.2025.108321_sbref0002","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","year":"2024"},{"key":"10.1016\/j.ijid.2025.108321_bib0003","unstructured":"European AIDS Clinical Society. EACS guidelines version 12.1. 2024. https:\/\/eacs.sanfordguide.com\/ [accessed 14 November 2024]."},{"key":"10.1016\/j.ijid.2025.108321_sbref0004","series-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. 2021 update","year":"2021"},{"issue":"1","key":"10.1016\/j.ijid.2025.108321_bib0005","article-title":"Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to doravirine-based regimens in people with HIV","volume":"25","author":"Kousari","year":"2024","journal-title":"HIV Res Clin Pract"},{"issue":"1","key":"10.1016\/j.ijid.2025.108321_bib0006","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12879-022-07091-1","article-title":"Effects of different integrase strand transfer inhibitors on body weight in patients with HIV\/AIDS: a network meta-analysis","volume":"22","author":"Bai","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2025.108321_bib0007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.36469\/jheor.2020.13457","article-title":"Real-world assessment of weight change in people with HIV-1 after initiating integrase strand transfer inhibitors or protease inhibitors","volume":"7","author":"Chen","year":"2020","journal-title":"J Health Econ Outcomes Res"},{"issue":"6","key":"10.1016\/j.ijid.2025.108321_bib0008","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2025.108321_bib0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/QAI.0000000000003101","article-title":"Weight gain and metabolic effects in persons with HIV who switch to ART regimens containing integrase inhibitors or tenofovir alafenamide","volume":"92","author":"Palella","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2025.108321_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fendo.2018.00705","article-title":"The impact of weight gain during HIV treatment on risk of pre-diabetes, diabetes mellitus, cardiovascular disease, and mortality","volume":"9","author":"Kumar","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ijid.2025.108321_bib0011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijid.2021.07.030","article-title":"Long-term weight gain after initiating combination antiretroviral therapy in treatment-na\u00efve Asian people living with HIV","volume":"110","author":"Ando","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2025.108321_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-06500-0","article-title":"Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional study","volume":"15","author":"De Greef","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ijid.2025.108321_bib0013","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/cid\/ciad545","article-title":"Weight gain after antiretroviral therapy initiation and subsequent risk of metabolic and cardiovascular disease","volume":"78","author":"Bares","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108321_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ijid.2025.108321_bib0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12170-023-00714-5","article-title":"Obesity and cardiovascular risk among South Asian Americans","volume":"17","author":"Deshpande","year":"2023","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"2","key":"10.1016\/j.ijid.2025.108321_bib0016","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/oby.23639","article-title":"Obesity among Asian American people in the United States: a review","volume":"31","author":"Li","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ijid.2025.108321_bib0017","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1177\/0962280218781171","article-title":"Propensity score weighting analysis and treatment effect discovery","volume":"28","author":"Mao","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"10167","key":"10.1016\/j.ijid.2025.108321_bib0018","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2025.108321_bib0019","doi-asserted-by":"crossref","first-page":"ofae007","DOI":"10.1093\/ofid\/ofae007","article-title":"Final 192-week efficacy and safety results of the ADVANCE trial, comparing three first-line antiretroviral regimens","volume":"11","author":"Sokhela","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.108321_bib0020","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/QAD.0000000000003950","article-title":"Choice of antiretroviral therapy has low impact on weight gain","volume":"38","author":"Drechsler","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2025.108321_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2024.102630","article-title":"Effect of dolutegravir on weight changes and lipid profile compared with efavirenz in people living with HIV: a retrospective cohort study","volume":"18","author":"Setpakdee","year":"2025","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.ijid.2025.108321_bib0022","unstructured":"Thai AIDS Society. Thailand national guideline on HIV\/AIDS treatment and prevention 2021\/2022. 2021 https:\/\/www.thaiaidssociety.org. [accessed 12 September 2022]."},{"key":"10.1016\/j.ijid.2025.108321_bib0023","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3018(24)00183-8","article-title":"Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration","volume":"11","author":"Pantazis","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijid.2025.108321_bib0024","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2352-3018(23)00328-4","volume":"11","author":"Byonanebye","year":"2024","journal-title":"Lancet HIV"},{"issue":"3","key":"10.1016\/j.ijid.2025.108321_bib0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/cid\/ciae449","article-title":"A prospective, randomized, phase 4 trial to assess a protease inhibitor-based regimen switch strategy to manage integrase inhibitor-related weight gain","volume":"80","author":"Anderson","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108321_bib0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jac\/dkae392","article-title":"Comparing the long-term effectiveness and safety of dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate as first-line regimens: a real-life multicentre cohort","volume":"80","author":"Ciccullo","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2025.108321_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314003","article-title":"Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV","volume":"19","author":"Lee","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2025.108321_bib0028","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40121-024-00950-1","article-title":"Real-world effectiveness of dolutegravir\/lamivudine in people with HIV-1 in test-and-treat settings or with high baseline viral loads: TANDEM study subgroup analyses","volume":"13","author":"Benson","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"Suppl 1","key":"10.1016\/j.ijid.2025.108321_bib0029","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/QAI.0000000000003053","article-title":"Dolutegravir plus lamivudine dual-drug regimen in treatment-naive HIV-1-infected patients with high-level viral load: preliminary data from the real world","volume":"91","author":"Zhao","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"10.1016\/j.ijid.2025.108321_bib0030","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/cid\/ciae406","article-title":"Integrase strand transfer inhibitor-related changes in body mass index and risk of diabetes: a prospective study from the RESPOND cohort consortium","volume":"80","author":"Rupasinghe","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225005387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225005387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:52:16Z","timestamp":1784548336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225005387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"alternative-id":["S1201971225005387"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108321","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dolutegravir\/lamivudine versus bictegravir\/emtricitabine\/tenofovir alafenamide fumarate: Real-world assessment of effectiveness and weight Gain in na\u00efve people living with HIV of Asian OrigiN (DRAGON)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108321"}}